Alector (NASDAQ:ALEC) Trading 5.9% Higher

Share on StockTwits

Shares of Alector Inc (NASDAQ:ALEC) traded up 5.9% during mid-day trading on Monday . The company traded as high as $16.00 and last traded at $15.73, 365,894 shares traded hands during mid-day trading. An increase of 51% from the average session volume of 242,728 shares. The stock had previously closed at $14.85.

A number of equities analysts recently issued reports on the company. ValuEngine raised Alector from a “hold” rating to a “buy” rating in a report on Thursday, August 15th. Cowen reissued a “buy” rating on shares of Alector in a report on Wednesday, July 17th. Seven research analysts have rated the stock with a buy rating, Alector presently has an average rating of “Buy” and a consensus target price of $26.67.

The firm has a market capitalization of $1.08 billion and a price-to-earnings ratio of -3.43. The business has a fifty day moving average of $18.61. The company has a debt-to-equity ratio of 0.17, a current ratio of 6.18 and a quick ratio of 6.18.

Alector (NASDAQ:ALEC) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.03). The company had revenue of $6.92 million during the quarter. Sell-side analysts anticipate that Alector Inc will post -1.38 earnings per share for the current year.

In other Alector news, insider Robert Paul sold 2,000 shares of the stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $16.00, for a total transaction of $32,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Orbimed Advisors Llc sold 650,000 shares of the stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $17.90, for a total value of $11,635,000.00. The disclosure for this sale can be found here. Company insiders own 34.40% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Baillie Gifford & Co. bought a new position in Alector during the 1st quarter valued at $41,000. Wells Fargo & Company MN boosted its stake in Alector by 89.2% during the 2nd quarter. Wells Fargo & Company MN now owns 13,650 shares of the company’s stock valued at $259,000 after purchasing an additional 6,434 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Alector by 20.8% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 56,744 shares of the company’s stock valued at $1,079,000 after purchasing an additional 9,771 shares in the last quarter. Virtus ETF Advisers LLC bought a new position in Alector during the 2nd quarter valued at $251,000. Finally, Bank of New York Mellon Corp boosted its stake in Alector by 150.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 32,156 shares of the company’s stock valued at $611,000 after purchasing an additional 19,302 shares in the last quarter. 41.10% of the stock is owned by hedge funds and other institutional investors.

Alector Company Profile (NASDAQ:ALEC)

Alector, Inc, a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease.

Read More: What is Cost of Capital?

Receive News & Ratings for Alector Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alector and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

DD3 Acquisition Corp. Units  Shares Sold by Glazer Capital LLC
DD3 Acquisition Corp. Units Shares Sold by Glazer Capital LLC
$0.05 EPS Expected for Chicken Soup for The Soul Entrtnmnt Inc  This Quarter
$0.05 EPS Expected for Chicken Soup for The Soul Entrtnmnt Inc This Quarter
$0.70 Earnings Per Share Expected for Cardtronics PLC  This Quarter
$0.70 Earnings Per Share Expected for Cardtronics PLC This Quarter
DiamondPeak Holdings Corp.  Shares Sold by Glazer Capital LLC
DiamondPeak Holdings Corp. Shares Sold by Glazer Capital LLC
Chevron Co.  Shares Sold by Argent Capital Management LLC
Chevron Co. Shares Sold by Argent Capital Management LLC
Argent Capital Management LLC Has $17.43 Million Position in Wells Fargo & Co
Argent Capital Management LLC Has $17.43 Million Position in Wells Fargo & Co


 
© 2006-2019 Zolmax.